Acetylator phenotype in Behçet's disease

Advances in Experimental Medicine and Biology

Volumn 528, Issue , 2003, Pages 131-138

  Najim, Rafid A ^a   Sharquie, Khalifa E ^b   Al Janabi, Mahmood H ^a  

^a Department of Pharmacology ^*

^b UNIVERSITY OF BAGHDAD   (Iraq)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; HLA A ANTIGEN; HLA B ANTIGEN; HLA B51 ANTIGEN; HLA C ANTIGEN; ACETYLDAPSONE; DRUG DERIVATIVE; HLA BW51; HLA-BW51;

ACETYLATOR PHENOTYPE; ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG HYDROXYLATION; DRUG LIVER LEVEL; HEMOLYTIC ANEMIA; HUMAN; LIVER METABOLISM; PRIORITY JOURNAL; SIDE EFFECT; ACETYLATION; ADULT; BIOTRANSFORMATION; BLOOD; COMPARATIVE STUDY; FEMALE; GENETICS; IMMUNOLOGY; MALE; MIDDLE AGED; ONSET AGE; PHENOTYPE; REFERENCE VALUE;

ACETYLATION; ADULT; AGE OF ONSET; BEHCET SYNDROME; BIOTRANSFORMATION; DAPSONE; FEMALE; HLA-B ANTIGENS; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; REFERENCE VALUES;

EID: 0642338854     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (22)

1. Weber, W.W., and Hein, D.W., 1985, N-acetylation pharmacogenetics. Pharmacol. Rev. 37: 25-79.
2. Chen, M.L., Lee M.G., and Chiou W.L., 1983, Pharmacokinetics of drugs in blood III: Metabolism of procainamide and storage effects of blood samples. J. Pharma. Sci. 72: 572-574.
3. Sharquie, K.E., 1990, Behçet's disease. Postgrad. Doctor Middle East 13: 186-190.
4. Behçet, H., 1937, Über rezidivierende aphthöse, durch ein virus verursachte Geschwüre am Mund am Auge und den Genitalien. Dermatol. Wochenschr. 105: 1152-1157.
5. Sharquie K., 1984, Suppression of Behçet's disease with dapsone. Br. J. Dermatol. 110: 493-494.
6. Sharquie, K., Najim, R.A., and Abu-Raghif, A.R., 2002, Dapsone in treatment of Behçet's disease: a double blind, placebo- controlled crossover study. J. Dermatol., in press.
7. International Study Group for Behçet's disease, 1990, Criteria for diagnosis of Behçet's disease. Lancet 335: 1078-1080.
8. Philip, P.A., Gayed, S.L., and Rogers, H.J., 1984, A rapid method for determination of acetylation phenotype using dapsone. Br. J. Clin. Pharmacol. 17: 465-469.
9. Sorlie, D.E., 1995, Medical Biostatistics and Epidemiology: Examination and Board review. 1st ed., Appleton and Lange, Norwalk, Connecticut, pp. 47-88.
10. nd ed., pp. 105-111.
11. Ahmad, R.A., 1984, Acetylation in Iraqi population. In Proceeding of the First Scientific Congress, College of Medicine, University of Baghdad, p. 115.
12. Irashaid, Y.M., Al-Hadidi H.F., Aburijeie, M.A., et al., 1991, N-acetylation phenotyping using dapsone in a Jordanian population. Br. J. Clin. Pharmacol. 32: 289-293.
13. Islam, S.I., 1982, Polymorphic acetylation of sulphamethazine in rural Bedouin and urban dwellers in Saudi Arabia. Xenobiotica 12: 323-328.
14. Karim, A.K.M.B., Elferah, M.S., and Evans, D.A.P., 1981, Human acetylator polymorphism: estimate of allele frequency in Libya and details of global distribution. J. Med. Genet. 18: 325-330.
15. Hashem, N., Khalifa, S., and Nour, A., 1969, The frequency of isoniazide acetylase enzyme deficiency among Egyptians. Am. J. Phys. Anthropol. 31: 97-102.
16. Grant, D.M., Tang, B.K., and Kalow, W., 1983, Polymorphic N-acetylation of a caffeine metabolite. Clin. Pharmacol. Ther. 33: 355-359.
17. Horai, Y., and Ishizaki, T., 1988, N-acetylation polymorphism of dapsone in a Japanese population. Br. J. Clin. Pharmacol. 25: 487-494.
18. El-Yazigi, A., Chaleby, K., and Martin, C.R., 1989, Acetylator phenotypes of Saudi Arabians by a simplified caffeine metabolites test. J. Clin. Pharmacol. 29: 246-250.
19. Yazici, H., Chamberlain, M.A., Schreuder, T., et al., 1980, HLA antigen in Behçet's disease: A reapprasial by a comperative study of Turkish and British patients. Ann. Rheum. Dis. 39: 344.
20. Al-Rawi, Z.S., Sharquie, K.E., Khalifa, S.J., et al., 1986, Behçet's disease in Iraqi patients. Ann. Rheum. Dis. 45: 987-990.
21. Evans D.A.P., Manley K. A., and Mckusick, V.A., 1960, Genetic control of isoniazide metabolism in man. Br. Med. J. 2: 458-491.
22. Zuidema, J., Hilbers, E.S., and Merkus A., 1986, Clinical pharmacokinetics of dapsone. Clin. Pharmacokinet. 11: 299-314.